Waltham, United States
Minerva Biotechnologies, founded in 1999 and headquartered in the United States, is a clinical stage biopharmaceutical company noted for its tagline: "We see the future first." The company focuses on developing groundbreaking immunotherapies for solid tumor cancers and advanced cellular therapies for regenerative medicine.
The firm’s flagship endeavor, NCT04020575, is a first-in-human trial of huMNC2-CAR44, a pioneering CAR T therapy targeting the MUC1* growth factor receptor prevalent in 95% of metastatic breast cancer cases. With a strategy to expand current trials, they are introducing a second CAR-T product noted for its enhanced persistence.
Minerva is accelerating its robust pipeline which includes next-gen CAR-T solutions, a straight antibody therapeutic, and a small molecule therapeutic for combating cancer metastasis. The company's visionary team and collaborative culture are credited with its series of scientific breakthroughs.
After securing a $24.10M late-stage VC investment as of 01 January 2022, Minerva continues to attract attention as a potential game-changer in the biotechnology space.
